ALAMEDA, Calif., Nov. 1 /PRNewswire/ -- In a gene therapy study targeting the potential treatment of hemophilia A, Avigen (Nasdaq: AVGN) scientists today announced that a single administration of an adeno-associated vector (AAV) carrying the gene for factor VIII produced physiological levels of ...